nach oben

Erschienen in:

01.01.2023 | Review

Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/consensus guidance on the use of cannabinoids for gastrointestinal symptoms in patients with cancer

verfasst von: Bryony Alderman, David Hui, Sandip Mukhopadhyay, Carole Bouleuc, Amy A. Case, Koji Amano, Gregory B. Crawford, Giulia de Feo, Andrea Sbrana, Kimberson Tanco, Josephine To, Jessica Garsed, Mellar Davis

Erschienen in: Supportive Care in Cancer | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Gastrointestinal symptoms are common in patients with cancer, whether related to treatment or a direct effect of the disease itself. Patients may choose to access cannabinoids outside of their formal medical prescriptions to palliate such symptoms. However, clinical guidelines are lacking in relation to the use of such medicines for gastrointestinal symptoms in patients with cancer.

Methods

A systematic review of the evidence for the use of cannabinoids for symptom control in patients with cancer was undertaken. Search strategies were developed for Medline, Embase, PsychINFO, and the Cochrane Central Register of Controlled Trials, including all publications from 1975 up to 12 November 2021. Studies were included if they were randomized controlled trials of cannabinoids compared with placebo or active comparator in adult patients with cancer, regardless of type, stage, or treatment status. Articles for inclusion were agreed by all authors, and data extracted and summarized by two authors. Each study was scored according to the Jadad scale. This review was specifically for the purpose of developing guidelines for the use of cannabis for gastrointestinal symptoms, including chemotherapy-induced nausea and vomiting (CINV), chronic nausea, anorexia-cachexia syndrome, and taste disturbance.

Results

Thirty-six randomized controlled trials were identified that met the inclusion criteria for this review of gastrointestinal symptoms: 31 relating to CINV, one to radiotherapy-induced nausea and vomiting, and the remaining four to anorexia-cachexia and altered chemosensory disturbance. The populations for the randomized controlled trials were heterogeneous, and many studies were of poor quality, lacking clarity regarding method of randomization, blinding, and allocation concealment. For CINV, eleven RCTs showed improvement with cannabis compared to placebo, but out of 21 trials where cannabis was compared to other antiemetics for CINV, only 11 favoured cannabis.

Conclusion

Tetrahydrocannabinol (THC) and nabilone were more effective in preventing CINV when compared to placebo but are not more effective than other antiemetics. For refractory CINV, one study of THC:CBD demonstrated reduced nausea as an add-on treatment to guideline-consistent antiemetic therapy without olanzapine. The MASCC Guideline Committee found insufficient evidence to recommend cannabinoids for the management of CINV, nausea from advanced cancer, cancer-associated anorexia-cachexia, and taste disturbance. High-quality studies are needed to inform practice.

World Health Organisation. Alcohol, drugs and addictive behaviours unit. Cannabis. Available from: https://www.who.int/teams/mental-health-and-substance-use/alcohol-drugs-and-addictive-behaviours/drugs-psychoactive/cannabis [Accessed 8^th March 2022]

Bridgeman MB, Abazia DT (2017) Medicinal cannabis: history, pharmacology, and implications for the acute care setting. P T 42(3):180–188

Wilkie G, Sakr B, Rizack T (2016) Medical marijuana use in oncology: a review. JAMA Oncol 2(5):670–675. https://doi.org/10.1001/jamaoncol.2016.0155CrossRef

Multinational Association of Supportive Care in Cancer, 2018. Recommendations for MASCC guideline construction and the endorsement of externally generated guidelines. Available from: https://www.mascc.org/assets/Toolbox/PoliciesForms/mascc_guideline_policy_2018.pdf [Accessed 15th January 2022]

Sallan SE, Zinberg NE, Frei E 3rd (1975) Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 293(16):795–797. https://doi.org/10.1056/NEJM197510162931603CrossRef

Chang AE, Shiling DJ, Stillman RC et al (1979) Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med 91(6):819–824. https://doi.org/10.7326/0003-4819-91-6-819CrossRef

Kluin-Neleman JC, Neleman FA, Meuwissen OJ, Maes RA (1979) delta 9-Tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancer chemotherapy; a double-blind cross-over trial against placebo. Vet Hum Toxicol 21(5):338–340

Chang AE, Shiling DJ, Stillman RC et al (1981) A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 47(7):1746–1751. https://doi.org/10.1002/1097-0142(19810401)47:7%3c1746::aid-cncr2820470704%3e3.0.co;2-4CrossRef

Frytak S, Moertel CG, O’Fallon JR et al (1979) Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med. 91(6):825–830. https://doi.org/10.7326/0003-4819-91-6-825CrossRef

10.

Ungerleider JT, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison K (1982) Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. Cancer 50(4):636–645. https://doi.org/10.1002/1097-0142(19820815)50:4%3c636::aid-cncr2820500404%3e3.0.co;2-4CrossRef

11.

Orr LE, McKernan JF (1981) Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine. J Clin Pharmacol 21(S1):76S-80S. https://doi.org/10.1002/j.1552-4604.1981.tb02578.xCrossRef

12.

McCabe M, Smith FP, Macdonald JS, Woolley PV, Goldberg D, Schein PS (1988) Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Invest New Drugs 6(3):243–246. https://doi.org/10.1007/BF00175407CrossRef

13.

Lane M, Smith FE, Sullivan RA, Plasse TF (1990) Dronabinol and prochlorperazine alone and in combination as antiemetic agents for cancer chemotherapy. Am J Clin Oncol 13(6):480–484. https://doi.org/10.1097/00000421-199012000-00006CrossRef

14.

Lane M, Vogel CL, Ferguson J et al (1991) Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage 6(6):352–359. https://doi.org/10.1016/0885-3924(91)90026-zCrossRef

15.

Kleinman S, Weitzman SA, Cassem N, Andrews E (1983) Double blind trial of delta-9-tetrahydrocannabinol (THC) versus placebo as an adjunct to prochlorperazine for chemotherapy-induced vomiting. Curr Ther Res-Clin Exp 33(6 I):1014–7

16.

Neidhart JA, Gagen MM, Wilson HE, Young DC (1981) Comparative trial of the antiemetic effects of THC and haloperidol. J Clin Pharmacol 21(S1):38S-42S. https://doi.org/10.1002/j.1552-4604.1981.tb02571.xCrossRef

17.

Colls BM, Ferry DG, Gray AJ, Harvey VJ, McQueen EG (1980) The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy. N Z Med J 91(662):449–451

18.

Ahmedzai S, Carlyle DL, Calder IT, Moran F (1983) Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer 48(5):657–663. https://doi.org/10.1038/bjc.1983.247CrossRef

19.

Niiranen A, Mattson K (1985) A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol 8(4):336–340. https://doi.org/10.1097/00000421-198508000-00013CrossRef

20.

Jones SE, Durant JR, Greco FA, Robertone A (1982) A multi-institutional phase III study of nabilone vs. placebo in chemotherapy-induced nausea and vomiting. Cancer Treat Rev. 9(Suppl B):45–48. https://doi.org/10.1016/s0305-7372(82)80035-2CrossRef

21.

Johansson R, Kilkku P, Groenroos M (1982) A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy. Cancer Treat Rev. 9(Suppl B):25–33. https://doi.org/10.1016/s0305-7372(82)80032-7CrossRef

22.

Herman TS, Einhorn LH, Jones SE et al (1979) Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 300(23):1295–1297. https://doi.org/10.1056/NEJM197906073002302CrossRef

23.

Grimison P, Mersiades A, Kirby A et al (2020) Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Ann Oncol 31(11):1553–1560. https://doi.org/10.1016/j.annonc.2020.07.020CrossRef

24.

Einhorn LH, Nagy C, Furnas B, Williams SD (1981) Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol 21(S1):64S-69S. https://doi.org/10.1002/j.1552-4604.1981.tb02576.xCrossRef

25.

Levitt M (1982) Nabilone vs. placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Cancer Treat Rev 9(Suppl B):49–53CrossRef

26.

Steele N, Gralla RJ, Braun DW Jr, Young CW (1980) Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep 64(2–3):219–224

27.

Crawford SM, Buckman R (1986) Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study. Med Oncol Tumor Pharmacother 3(1):39–42. https://doi.org/10.1007/BF02934575CrossRef

28.

Pomeroy M, Fennelly JJ, Towers M (1986) Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother Pharmacol 17(3):285–288. https://doi.org/10.1007/BF00256701CrossRef

29.

Niederle N, Schütte J, Schmidt CG (1986) Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Klin Wochenschr 64(8):362–365. https://doi.org/10.1007/BF01728184CrossRef

30.

Wada JK, Bogdon DL, Gunnell JC, Hum GJ, Gota CH, Rieth TE (1982) Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy. Cancer Treat Rev. 9(Suppl B):39–44. https://doi.org/10.1016/s0305-7372(82)80034-0CrossRef

31.

Meiri E, Jhangiani H, Vredenburgh JJ et al (2007) Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 23(3):533–543. https://doi.org/10.1185/030079907x167525CrossRef

32.

Duran M, Pérez E, Abanades S et al (2010) Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol 70(5):656–663. https://doi.org/10.1111/j.1365-2125.2010.03743.xCrossRef

33.

Hutcheon AW, Palmer JB, Soukop M et al (1983) A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy. Eur J Cancer Clin Oncol 19(8):1087–1090. https://doi.org/10.1016/0277-5379(83)90032-9CrossRef

34.

Chow R, Valdez C, Chow N et al (2020) Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis. Support Care Cancer 28(5):2095–2103. https://doi.org/10.1007/s00520-019-05280-4CrossRef

35.

Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S (2015) Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev. 2015(11):CD009464. https://doi.org/10.1002/14651858.CD009464.pub2CrossRef

36.

Machado Rocha FC, Stéfano SC, De Cássia HR, Rosa Oliveira LM, Da Silveira DX (2008) Therapeutic use of cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl) 17(5):431–443. https://doi.org/10.1111/j.1365-2354.2008.00917.xCrossRef

37.

Tramèr MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ (2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323(7303):16–21. https://doi.org/10.1136/bmj.323.7303.16CrossRef

38.

Cunningham D, Bradley CJ, Forrest GJ et al (1988) A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol 24(4):685–689. https://doi.org/10.1016/0277-5379(88)90300-8CrossRef

39.

Lucraft HH, Palmer MK (1982) Randomised clinical trial of levonantradol and chlorpromazine in the prevention of radiotherapy-induced vomiting. Clin Radiol 33(6):621–622. https://doi.org/10.1016/s0009-9260(82)80383-8CrossRef

40.

Cannabis-In-Cachexia-Study-Group, Strasser F, Luftner D et al (2006) Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 24(21):3394–3400. https://doi.org/10.1200/JCO.2005.05.1847CrossRef

41.

Turcott JG, Del Rocío Guillen Núñez M, Flores-Estrada D et al (2018) The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer 26(9):3029–3038. https://doi.org/10.1007/s00520-018-4154-9CrossRef

42.

Jatoi A, Windschitl HE, Loprinzi CL et al (2002) Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 20(2):567–573. https://doi.org/10.1200/JCO.2002.20.2.567CrossRef

43.

Brisbois TD, de Kock IH, Watanabe SM et al (2011) Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol 22(9):2086–2093. https://doi.org/10.1093/annonc/mdq727CrossRef

44.

Taha T, Meiri D, Talhamy S, Wollner M, Peer A, Bar-Sela G (2019) Cannabis impacts tumor response rate to nivolumab in patients with advanced malignancies. Oncologist 24(4):549–554CrossRef

45.

Roila F, Warr D, Hesketh PJ et al (2017) 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following moderately emetogenic chemotherapy. Support Care Cancer 25(1):289–294. https://doi.org/10.1007/s00520-016-3365-1CrossRef

46.

Herrstedt J, Roila F, Warr D et al (2017) 2016 Updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support Care Cancer 25(1):277–288. https://doi.org/10.1007/s00520-016-3313-0CrossRef

Titel: Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/consensus guidance on the use of cannabinoids for gastrointestinal symptoms in patients with cancer
verfasst von: Bryony Alderman
David Hui
Sandip Mukhopadhyay
Carole Bouleuc
Amy A. Case
Koji Amano
Gregory B. Crawford
Giulia de Feo
Andrea Sbrana
Kimberson Tanco
Josephine To
Jessica Garsed
Mellar Davis
Publikationsdatum: 01.01.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 1/2023
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-022-07480-x

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/consensus guidance on the use of cannabinoids for gastrointestinal symptoms in patients with cancer